


Claims

1. A phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



5 wherein

R¹ represents alkyl optionally substituted by one or two substituents selected from the group consisting of alkoxy, amino, alkylamino, di(alkyl)amino, alkanoyloxy, hydroxy, carboxy, alkoxycarbonyl, cycloalkylphenoxy, halogen, morpholino, carbamoyl, alkylsulfonylamino, phenoxy optionally substituted by cycloalkyl, and 3-8 membered saturated ring optionally having one or two N atom which ring optionally substituted by hydroxy or alkanoyl,

15 or 3-8 membered saturated or unsaturated ring optionally having one or two hetero atoms selected from the group consisting of N and O, and which ring is optionally substituted by one or two substituents selected from the group consisting of alkyl, halogen, alkoxy, nitro, amino, cyano, alkylamino, di(alkyl)amino, 4-7 membered saturated cyclic amine optionally substituted by hydroxy, and mono-, di-, or tri-halogen substituted alkyl;

R^2 represents $-COR^{21}$, $-(CH_2)_n-R^{21}$ or tert-butyl,

Wherein R²¹ is alkoxy, hydroxy, mono-, di-, or tri- halogen substituted alkyl,

20 or 3-8 membered saturated or unsaturated ring optionally having one or two heteroatoms selected from the group consisting of N, O, and S and which ring is optionally substituted by one or two substituents independently selected from the group consisting of alkanoyl, halogen, benzyl, alkoxycarbonyl, haloalkyloxy-carbonyl, cyano, hydroxy, amino, alkylamino, di(alkyl)amino, cycloalkylamino, alkoxycarbonyl, sulfamoyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, alkanoyl, alkanoylamino, carbamoyl, alkylcarbamoyl, di-(alkyl)carbamoyl, alkylsulfonyl,

25

-100-

alkyl optionally substituted by alkoxycarbonyl or mono-, di-, or tri-halogen, alkoxy optionally substituted by mono-, di-, or tri- halogen, and alkylthio optionally substituted by mono-, di-, or tri- halogen;

n is 0 or 1;

5 R³ and R⁴ independently represent hydrogen, halogen, cyano, hydroxy, amino, alkylamino, di(alkyl)amino, cycloalkylamino, carboxy, alkoxycarbonyl, sulfamoyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, alkanoyl, alkanoylamino, carbamoyl, alkylcarbamoyl, di-(alkyl)carbamoyl, alkylsulfonyl, alkyl optionally substituted by hydroxy, alkoxycarbonyl or mono-, di-, or tri-halogen, alkoxy optionally substituted by mono-, di-, or tri- halogen, or alkylthio optionally substituted by mono-, di-, or tri- halogen;

10

R⁵ represents hydrogen, hydroxy, nitro, cyano, halogen, sulfamoyl, alkylsulfonyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, -(CH₂)_m-CO-R⁵⁰, -(CH₂)_m-R⁵¹, -NR⁵²R⁵³, or -OR⁵⁴,

15 wherein m is 0, 1, 2, or 3

R⁵⁰ is hydroxy, hydrogen, alkoxy, morpholino, di(phenyl)methoxy, di(halogen substituted phenyl)methoxy, -NR⁵⁰¹R⁵⁰² (wherein said R⁵⁰¹ and R⁵⁰² independently represent hydrogen, alkoxyalkyl, alkyl, hydroxyalkyl, alkoxycarbonylalkyl, or carboxyalkyl or

20 R⁵⁰¹ and R⁵⁰² together form with the adjuscent N atom, morpholino, piperazino optionally substituted by oxo, or 4-7 membered saturated cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl) or alkyl optionally substituted by halogen,

25 R⁵¹ is hydrogen, hydroxy, or -NR⁵¹¹R⁵¹² (wherein said R⁵¹¹ and R⁵¹² independently represent hydrogen, alkoxyalkyl, alkyl, hydroxyalkyl, alkoxycarbonylalkyl, or carboxyalkyl, or R⁵¹¹ and R⁵¹² together form with the adjuscent N atom, 4-7 membered saturated cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl),

30

5 R⁵² and R⁵³ independently represent hydrogen, alkyl, hydroxy, cycloalkylcarbonyl, hydroxyalkyl, alkylsulfonyl, hydroxyalkylcarbonyl, carboxyalkylcarbonyl, alkanoyloxyalkylcarbonyl, or alkoxy carbonylalkylcarbonyl, or R⁵² and R⁵³ together form with adjacent N atom, morpholino, cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl,

10 R⁵⁴ represents alkyl optionally substituted by morpholino, amino, di(alkyl)amino, carboxy, alkoxy carbonyl, or mono-, di-, or tri- halogen, or piperazino substituted by carboxy;

15 R⁶ and R⁷ independently represents hydrogen, morpholino, hydroxypyrrolidinylcarbonyl, hydroxyalkylaminocarbonyl, cyano, hydroxy, hydroxyalkyl, hydroxyamino, carboxy, fluoro, chloro, bromo, nitro, amino, alkylamino, di(alkyl)amino, cycloalkylamino, alkoxy carbonyl, sulfamoyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, alkanoyl, alkanoylamino, carbamoyl, diphenylmethoxy carbonyl, alkylcarbamoyl, di-(alkyl)carbamoyl, alkylsulfonyl, alkyl optionally substituted by alkoxyalkyl(alkyl)amino, di(alkyl)amino, alkoxy carbonyl, carboxy, or mono-, di-, or tri-halogen, alkoxy optionally substituted by morpholino, di(alkyl)amino, or mono-, di-, or tri- halogen, or C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen

20 or R⁶ and R⁷ together form phenyl fused to adjacent phenyl; and

X represents CR¹⁰R¹¹, NR¹², S, O, SO₂, or SO

wherein R¹⁰, R¹¹, and R¹² independently represent hydrogen or methyl.

2. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1:

25 wherein

X represents CH₂, NH, S, O, SO₂, or SO;

R¹ represents C₃ to C₈ cycloalkyl,

C₁-C₆ alkyl optionally substituted by one or two substituents selected from the group consisting of C₁-C₆ alkoxy, amino, C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, C₁-C₆

- 102 -

alkanoyloxy, hydroxy, C₃-C₈ cycloalkyl, carboxy, C₁-C₆ alkoxy carbonyl, C₃-C₈ cycloalkyl phenoxy, halogen, morpholino, and pyrrolidinyl,
 5 pyridyl, pyrrolidinyl, piperidinyl optionally substituted by methyl, or phenyl optionally substituted by one selected from the group consisting of halogen, C₁-C₆ alkoxy, nitro, amino, cyano, C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, and mono-, di- or tri- halogen substituted C₁-C₆ alkyl,

¹⁰ R² represents -COR²¹ or -(CH₂)_n-R²¹, wherein R²¹ represents mono-, di-, tri- halogen substituted C₁-C₆ alkyl, morpholino, C₁-C₆ alkoxy, hydroxy, C₃ to C₈ cycloalkyl, pyridyl, furanyl, thiophenyl, pyrrolidinyl, piperidinyl optionally substituted by one substituent selected from the group consisting of benzyl, C₁-C₆ alkoxycarbonyl, and halo C₁-C₆ alkyloxycarbonyl, or phenyl optionally substituted by one substituent selected from the group consisting of C₁-C₆ alkyl, halogen, C₁-C₆ alkoxy, and mono-, di-, or tri- halogen substituted C₁-C₆alkyl;

n is 0 or 1;

15 R³ and R⁴ independently represent hydrogen, halogen, cyano, hydroxy, amino, C₁₋₆ alkyl-amino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, sulfamoyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, di-(C₁₋₆ alkyl)carbamoyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkyl optionally substituted by C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen, or C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri-halogen;

20

R^5 represents hydrogen, nitro, cyano, hydroxy, halogen, sulfamoyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylaminosulfonyl, di(C_1-C_6 alkyl)aminosulfonyl, $-(CH_2)_m-CO-R^{50}$, $-(CH_2)_m-R^{51}$, $-NR^{52}R^{53}$, or $-OR^{54}$,

m is 0, 1, 2, or 3

R⁵⁰ is hydroxy, hydrogen, C₁-C₆alkoxy, morpholino, diphenylmethoxy, -NR⁵⁰¹R⁵⁰² (wherein said R⁵⁰¹ and R⁵⁰² independently represent hydrogen, C₁-C₆alkoxyalkyl, C₁-C₆alkyl, hydroxy C₁-C₆alkyl, C₁-C₆alkoxycarbonyl C₁-C₆alkyl, or carboxy C₁-C₆alkyl or R⁵⁰¹ and R⁵⁰² together form with the adjacent N atom morpholino, 4-6 membered saturated cyclic amino

optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl) or C₁-C₆ alkyl optionally substituted by halogen,

5 R⁵¹ is hydrogen, hydroxy, or -NR⁵¹¹R⁵¹² (wherein said R⁵¹¹ and R⁵¹² independently represent hydrogen, C₁-C₆ alkoxyalkyl, C₁-C₆ alkyl, hydroxyalkyl, C₁-C₆ alkoxy carbonylalkyl, or carboxyalkyl or R⁵¹¹ and R⁵¹² together form with the adjacent N atom, 4-7 membered saturated cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl)

10 R⁵² and R⁵³ independently represent hydrogen, C₁-C₆ alkyl, hydroxy, C₃-C₈cycloalkylcarbonyl, or hydroxy C₁-C₆ alkyl or R⁵² and R⁵³ together form with adjacent N atom, morpholino, 4-7 membered saturated cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl

15 R⁵⁴ represents alkyl optionally substituted by morpholino, amino, or di(alkyl) amino, or mono-, di-, or tri- halogen; and

20 R⁶ and R⁷ independently represent hydrogen, morpholino, hydroxypyrrolidinylcarbonyl, hydroxyC₁-C₆alkylaminocarbonyl, cyano, hydroxy, hydroxyC₁-C₆alkyl, hydroxyamino, carboxy, fluoro, chloro, bromo, nitro, amino, C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, C₃-C₈ cycloalkylamino, C₁-C₆ alkoxy carbonyl, sulfamoyl, C₁-C₆ alkylaminosulfonyl, di(C₁-C₆ alkyl)aminosulfonyl, C₁-C₆ alkanoyl, C₁-C₆ alkanoylamino, carbamoyl, diphenylmethyloxycarbonyl, C₁-C₆ alkylcarbamoyl, di-(C₁-C₆ alkyl)carbamoyl, C₁-C₆ alkylsulfonyl, C₁-C₆ alkyl optionally substituted by alkoxyalkyl(alkyl)amino, di(alkyl)amino, C₁-C₆ alkoxy carbonyl, carboxy, or mono-, di-, or tri-halogen, C₁-C₆ alkoxy optionally substituted by morpholino, di(alkyl)amino, or mono-, di-, or tri-halogen, or C₁-C₆ alkylthio optionally substituted by mono-, di-, or tri-halogen

25 or R⁶ and R⁷ together form phenyl fused to adjacent phenyl.

30 3. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

-104-

X represents CH_2 , NH, S, or SO;

R¹ represents cyclopropyl, pyridyl,
phenyl optionally substituted by halogen, C₁-C₆alkoxy, nitro, amino, cyano, C₁-C₆alkylamino, di(C₁-C₆alkyl)amino, or halogen substituted C₁-C₆alkyl,

5 C₁-C₆ alkyl optionally substituted by one or two substituents selected from the group consisting of C₁-C₆alkoxy, amino, C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, C₁-C₆ alkanoyloxy, hydroxy, C₃-C₈ cycloalkyl, carboxy, C₁-C₆ alkoxy carbonyl, C₃-C₈ cycloalkylphenoxy, halogen, morpholino, and pyrrolidinyl,
pyrrolidinyl, or piperidinyl optionally substituted by methyl;

10 R² represents -COR²¹ or -(CH₂)_n-R²¹, wherein R²¹ represents mono-, di- or tri-halogen substituted alkyl, morpholino, C₁-C₆alkoxy, hydroxy, C₃ to C₈ cycloalkyl, pyridyl, furanyl, thiophenyl, pyrrolidinyl, piperidinyl optionally substituted by one selected from the group consisting from benzyl, C₁-C₆alkoxycarbonyl, and haloC₁-C₆alkyloxycarbonyl, or phenyl optionally substituted by one selected from the group consisting of C₁-C₆ alkyl, halogen, C₁-C₆ alkoxy, and mono-, di- or tri-halogen substituted C₁-C₆alkyl;

15 n is 0 or 1;

R³ and R⁴ independently represent hydrogen, halogen, methyl, or amino;

20 R⁵ represents hydrogen, morpholino, hydroxypyrrolidinyl carbonyl, hydroxyalkylamino-carbonyl, cyano, hydroxy, hydroxyalkyl, hydroxyamino, carboxy, fluoro, chloro, bromo, nitro, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, sulfamoyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, diphenylmethyloxycarbonyl, C₁₋₆ alkylcarbamoyl, di-(C₁₋₆ alkyl)carbamoyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkyl optionally substituted by alkoxyalkyl(alkyl)amino, di(alkyl)amino, C₁₋₆ alkoxy carbonyl, carboxy, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by morpholino, di(alkyl)amino, or substituted by mono-, di-, or tri- halogen, or C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen; and

25 R⁶ and R⁷ represent hydrogen,
or R⁶ and R⁷ together form phenyl fused to adjacent phenyl.

30

4. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

X represents CH₂, NH, or S;

5 R¹ represents cyclopropyl, pyridyl, phenyl optionally substituted by halogen, alkoxy, nitro, amino, cyano, alkylamino, di(alkyl)amino, or halogen substituted alkyl, C₁-C₆ alkyl optionally substituted by one or two substituents selected from the group consisting of alkoxy, amino, C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, C₁-C₆ alkanoyloxy, hydroxy, C₃-C₈ cycloalkyl, carboxy, C₁-C₆ alkoxy carbonyl, C₃-C₈ 10 cycloalkylphenoxy, halogen, morpholino, and pyrrolidinyl, pyrrolidiny, or piperidiny optionally substituted by methyl.

5. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

15 X represents CH₂, NH, or S;

R² represents -COR²¹, -(CH₂)_nR²¹, wherein R²¹ is phenyl optionally substituted by C₁-C₆ alkyl, halogen, halogen substituted alkyl or alkoxy and n is 0 or 1.

6. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

20 wherein

X represents CH₂, NH, or S;

R³ and R⁴ independently represent hydrogen, halogen, methyl, amino; and

25 R⁵ represents hydrogen, morpholino, hydroxypyrrolidinylcarbonyl, hydroxyalkyl-aminocarbonyl, cyano, hydroxy, hydroxyalkyl, hydroxyamino, carboxy, fluoro, chloro, bromo, nitro, amino, C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, C₃-C₈ cyclo-alkylamino, C₁-C₆ alkoxy carbonyl, sulfamoyl, C₁-C₆ alkylaminosulfonyl, di(C₁-C₆ alkyl)aminosulfonyl, C₁-C₆ alkanoyl, C₁-C₆ alkanoylamino, carbamoyl, diphenylmethyloxycarbonyl, C₁-C₆ alkylcarbamoyl, di-(C₁-C₆ alkyl)carbamoyl, C₁-C₆ alkylsulfonyl,

C₁₋₆ alkyl optionally substituted by alkoxyalkyl(alkyl)amino, di(alkyl)amino, C₁₋₆ alkoxy carbonyl, carboxy, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by morpholino, di(alkyl)amino, or substituted by mono-, di-, or tri-halogen, or C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri-halogen; and

5 R⁶ and R⁷ represents hydrogen.

7. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said phenyltriazole derivative of the formula (I) is selected from the group consisting of:

(4-{3-cyclopropyl-5-[(diphenylmethyl)thio]-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

10 (4-{3-[(diphenylmethyl)thio]-5-ethyl-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

(4-{3-[(diphenylmethyl)thio]-5-propyl-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

[4-(3-cyclopropyl-5-{{(2-methylphenyl)(phenyl)methyl}thio}-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

15 [4-(3-{{[bis(4-chlorophenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl}phenyl]dimethylamine;

[4-(3-cyclopropyl-5-{{(4-methylphenyl)(phenyl)methyl}thio}-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

[4-(3-{{[bis(4-fluorophenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl}phenyl]dimethylamine;

20 [4-(3-{{(4-chlorophenyl)(phenyl)methyl}thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

(4-{3-cyclobutyl-5-[(diphenylmethyl)thio]-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

(4-{3-butyl-5-[(diphenylmethyl)thio]-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

25 [4-(3-{{[bis(4-methylphenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl}phenyl]dimethylamine;

{4-[3-cyclopropyl-5-({phenyl[4-(trifluoromethyl)phenyl]methyl}thio)-4H-1,2,4-triazol-4-yl]phenyl}dimethylamine;

[4-(3-{{[4-chlorophenyl](cyclohexyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

3-[{(diphenylmethyl)thio]-5-ethyl-4-(4-isopropylphenyl)-4H-1,2,4-triazole;

{4-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl]phenyl}dimethylamine;

[4-(3-{{[bis(4-chlorophenyl)methyl]thio}-5-propyl-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

3-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-propyl-4H-1,2,4-triazol-4-yl]benzoic acid;

3-{{5-{{[bis(4-chlorophenyl)methyl]thio}-4-[4-(dimethylamino)phenyl]-4H-1,2,4-triazol-3-yl}propan-1-ol};

3-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl]benzoic acid;

3-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl]phenol;

3-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-propyl-4H-1,2,3-triazol-4-yl]benzoic acid;

15 3-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl]benzoic acid;

5-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl]-2-(dimethyl-amino)benzoic acid;

1-[4-(3-{{[bis(4-chlorophenyl)methyl]thio}-5-propyl-4H-1,2,4-triazol-4-yl)phenyl]-piperidine-3-carboxylic acid; and

20 1-{{4-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl]-phenyl}-piperidine-3-carboxylic acid.

8. A medicament comprising a phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 in as an active ingredient.

25 9. The medicament as claimed in claim 8, further comprising one or more pharmaceutically acceptable excipients.

10. The medicament as claimed in claim 8, wherein said phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a GABAb agonist.
11. The medicament as claimed in claim 8 for the treatment and/or prevention of an urological disorder or disease.
5
12. The medicament as claimed in claim 11, wherein said urological disorder or disease is urge urinary incontinence, overactive bladder, benign prostatic hyperplasia.
13. The medicament as claimed in claim 11 for the treatment and/or prevention of pain.
14. The medicament as claimed in claim 11 for the treatment and/or prevention of spasticity
10 and motor control disorders, epilepsy, cognitive defects, psychiatric disorders, alcohol dependence and withdrawal, feeding behaviour, cardiovascular, respiratory disorders, or gastrointestinal disorders.
15. Use of a compound according to claim 1 for manufacturing a medicament for the treatment and/or prevention of an urological disorder or disease.
- 15 16. Use of a compound according to claim 1 for manufacturing a medicament for the treatment and/or prevention of pain.
17. Process for controlling an urological disorder or disease in humans and animals by administration of an GABAb-agonistically effective amount of a compound according to
claim 1.
- 20 18. Process for controlling pain in humans and animals by administration of a GABAb-agonistically effective amount of a compound according to claim 1.